Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223

BACKGROUND: Radium-223 dichloride is an alpha emitter approved for metastatic castration-resistant prostate cancer (mCRPC). Unfortunately, little data are available on the prognostic factors during radium-223-based therapy. PATIENTS AND METHODS: Patients with histologically confirmed progressive CRP...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Onco Targets Ther
Prif Awduron: Roviello, Giandomenico, Gallicchio, Rosj, Bozza, Giovanni, Rodriquenz, Maria Grazia, Aieta, Michele, Storto, Giovanni
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Dove Medical Press 2018
Pynciau:
Rapid Communication
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6301292/
https://ncbi.nlm.nih.gov/pubmed/30588025
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S174206
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg